Initial evaluation of pulmonary abnormalities: CT-guided fine-needle aspiration biopsy and fluoride-18 fluorodeoxyglucose positron emission tomography correlation

Diagnostic Cytopathology

Volumn 22, Issue 2, 2000, Pages 92-96

  Collins, Brian T ^a,b   Lowe, Val J ^a   Dunphy, Frank R ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

Author keywords

Cytology; FDG PET; Needle biopsy; Neoplasia

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; ASPIRATION BIOPSY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; LUNG TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

BIOPSY, NEEDLE; CARCINOMA; CARCINOMA, BRONCHOGENIC; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THORACIC NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033984911     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0339(200002)22:2<92::AID-DC6>3.0.CO;2-2     Document Type: Article

References (20)

1. Duhaylongsod FG, Lowe VJ, Patz EF, Vaughn AL, Coleman RE, Wolfe WG. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995;110:130-140.
2. Patz EF, Lowe VJ, Huffman JM, Paine SS, Burrowes P, Coleman RE, Goodman PC. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993;188:487-490.
3. Patz EF, Lowe VJ, Hoffman JM, Paine SS, Harris LK, Goodman PC. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 1994;191:379-382.
4. Hebert ME, Lowe VJ, Hoffman JM, Patz EF, Anscher MS. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. Am J Clin Oncol 1996;19:416-421.
5. Lowe VJ, Hoffman JM, DeLong DM, Patz EF, Coleman RE. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994;35:1771-1776.
6. Lowe VJ, DeLong DM, Hoffman JM, Coleman RE. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med 1995;36:883-887.
7. Lowe VJ, Duhaylongsod FG, Patz EF, Delong DM, Hoffman JM, Wolfe WG, Coleman RE. Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology 1997;202:435-439.
8. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, Karis J, Hubner K, Delbeke D, Heiberg EV, Patz EF, Coleman RE. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998;16:1075-1084.
9. Dewan NA, Reeb SD, Gupta NC, Gobar LS, Scott WJ. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest 1995;108:441-446.
10. Kapucu LO, Meltzer CC, Townsend DW, Keenan RJ, Luketich JD. Fluorine-18-fluorodeoxyglucose uptake in pneumonia. J Nucl Med 1998;39:1267-1269.
11. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A, Deneffe GJ, Nackaerts KL, Verschakelen JA, Lerut TE, Mortelmans LA, Demedts MG. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998;16:2142-2149.
12. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group. Chest 1997;112:1480-1486.
13. Guhlmann A, Storck M, Kotzerke J, Moog F, Sunder-Plassmann L, Reske SN. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET). Thorax 1997;52:438-441.
14. Steinert HC, Hauser M, Allemann F, Engel H, Berthold T, von Schulthess GK, Weder W. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997:202:441-446.
15. Bury T, Paulus P, Dowlati A, Corhay JL, Weber T, Ghaye B, Schoffers J, Limet R, Albert A, Rigo P, Radermecker M. Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. Eur Respir J 1996;9:2560-2564.
16. Sasaki M, Ichiya Y, Kuwabara Y, Akashi Y, Yoshida T, Fukumura T, Murayama S, Ishida T, Sugio K, Masuda K. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med 1996;23:741-747.
17. Wong WL, Chevretton EB, McGurk M, Hussain K, Davis J, Beaney R, Baddeley H, Tierney P, Maisey M. A prospective study of PET-FDG imasing for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol 1997;22:209-214.
18. Changlai SP, Kao CH, Chieng PU. 18f-2-fluoro-2-deoxy-d-glucose positron emission tomography of head and neck in patients with nasopharyngeal carcinomas. Oncol Rep 1997;4:1331-1334.
19. Pasquali C, Rubello D, Sperti C, Gasparoni P, Liessi G, Chierichetti F, Ferlin G, Pedrazzoli S. Neuroendocrine tumor imaging - can F-18-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 1998;22:588-592.
20. Weder W, Schmid RA, Bruchhaus H, Hillinger S, von Schulthess GK, Steinert HC. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998;66:886-893.